针对RAS的治疗策略取得了进展:从小分子抑制剂到化向化体的蛋白质分解
Xinchen Lu1,2,3, Jinmei Jin1, Ye Wu1
1Shanghai Frontiers Science Center for Chinese Medicine Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Medicinal research reviews
|November 27, 2023
概括
鼠肉瘤 (RAS) 基因突变导致致命的癌症. 针对蛋白质溶解的嵌合体 (PROTACs) 提供了一种新的策略,以克服RAS突变癌症的耐药性,解决经典抑制剂的局限性.
科学领域:
- 在瘤学瘤学.
- 化学生物学 化学生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 鼠肉瘤 (RAS) 基因突变是多种致命癌症的关键驱动因素.
- 获得药物耐药性限制了当前RAS亚型特定抑制剂的临床疗效.
研究的目的:
- 审查RAS抑制剂当前的进展.
- 专注于蛋白质溶解向嵌合体 (PROTACs) 作为对抗RAS突变和耐药性的战略.
主要方法:
- 关于RAS抑制剂的文献综述.
- 探索用于向RAS突变的PROTAC技术.
- 分析PROTACs在克服耐药性的潜力.
主要成果:
- 对于"无法治疗"的目标,PROTACs显示出显著的治疗潜力.
- 在RAS突变的癌症中,PROTAC提供了一种独特的机制来对抗获得的耐药性.
- PROTACs是一种有希望的策略,可以克服经典RAS抑制剂的局限性.
结论:
- PROTACs代表了一种可行的策略,以解决经典RAS抑制剂的瓶.
- 用PROTACs准RAS突变和下游效应因子对癌症治疗具有前途.
- 对PROTAC的进一步研究对于开发针对RAS驱动癌症的有效疗法至关重要.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
The Ras Gene
6.2K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.2K
Small GTPases - Ras and Rho
4.0K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
4.0K
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
Conservative Site-specific Recombination and Phase Variation
6.0K
Because the DNA segments are cut and reorganized in a direction-specific manner, site-specific recombination has emerged as an efficient genetic engineering technique. Flippase and Cyclization recombinases or Flp and Cre, respectively, are two members of the tyrosine recombinase family derived from bacteriophages, that are used to mediate site-specific DNA insertions, deletions, and targeted expression of proteins in mammalian cell lines.
The recognition sites for Cre recombinase called LoxP...
The recognition sites for Cre recombinase called LoxP...
6.0K


